InvestorsHub Logo
Followers 127
Posts 3172
Boards Moderated 0
Alias Born 08/24/2015

Re: None

Thursday, 08/15/2019 9:06:46 PM

Thursday, August 15, 2019 9:06:46 PM

Post# of 703267
On a different note;

Today's online first article from Lancet Oncology showing 4 year survival for Keytruda, paid for by BMY. I find this no coincidence considering where NWBO is regarding this time frame. Between Optune crowing about 5 year survival, now BMY paying for a 4 year OS follow up to their top immune therapy it kind of makes me wonder what they’re bracing for.

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30407-3/fulltext
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News